Clinical Trials Logo

Elevated Blood Pressure clinical trials

View clinical trials related to Elevated Blood Pressure.

Filter by:
  • None
  • Page 1

NCT ID: NCT03764020 Not yet recruiting - Clinical trials for Elevated Blood Pressure

Trial of Oral Melatonin in Elevated Blood Pressure

MRCTEBP
Start date: January 1, 2019
Phase: Phase 3
Study type: Interventional

Since, lowering blood pressure (BP) in elevated blood pressure individuals represents an excellent opportunity to for primary prevention of hypertension (HTN). Therefore, it is planned to use a safe treatment option - oral melatonin supplementation - associated with lifestyle interventions according to the American college of cardiology/American heart association (ACC/AHA) 2013 guideline in elevated blood pressure individuals to mitigate systolic and diastolic BP and ultimately, to prevent the development of HTN. Hypothesis: Melatonin therapy can lower the systolic and diastolic BP of elevated blood pressure individuals Melatonin can attenuate levels of circulatory biomarkers of Hs- CRP, Cholesterol, LDL-c and triglyceride

NCT ID: NCT03716960 Completed - Hypertension Clinical Trials

The Effects of Pumpkin Seed Oil Supplementation on Cardiovascular Function in Postmenopausal Women.

Start date: September 1, 2017
Phase: N/A
Study type: Interventional

Postmenopausal women have a higher prevalence of cardiovascular (CV) disease than age-match men. Growing evidence from rat studies have demonstrated CV-protective effects of pumpkin seed oil (PSO). The investigators hypothesis is that PSO would improve CV health in postmenopausal women.

NCT ID: NCT03626363 Recruiting - Clinical trials for Elevated Blood Pressure

Mindfulness and Neural Cardiovascular Control in Humans

Start date: September 4, 2018
Phase: N/A
Study type: Interventional

This study evaluates the impact of mindfulness-based stress reduction (MBSR) on sympathetic nerve activity and arterial stiffness. The investigator's central hypothesis is that MBSR will reduce sympathetic activity and arterial stiffness.

NCT ID: NCT03508739 Recruiting - Hypertension Clinical Trials

Glucagon-like Peptide-1 Metabolism and Acute Neprilysin Inhibition

Start date: June 1, 2018
Phase: Phase 3
Study type: Interventional

Type 2 diabetes is common, increases in prevalence with age, and patients with diabetes have an increased risk of cardiovascular disease. A relatively new cardiovascular medication currently used for the treatment of heart failure in the United States inhibits an enzyme that breaks down a variety of signaling hormones. This clinical trial tests if it may also be a target for the treatment of diabetes by decreasing the breakdown of a hormone that increases insulin release after a meal.

NCT ID: NCT03370991 Recruiting - Hypertension Clinical Trials

Blueberries for Improving Vascular Endothelial Function in Postmenopausal Women With Elevated Blood Pressure

Start date: December 2, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

Postmenopausal women are at an increased risk of developing cardiovascular disease (CVD) largely due to accelerated aging-related modifications to vascular health following menopause. The vascular endothelium is responsible for producing chemicals that are essential for proper vasodilation and blood flow and therefore is involved in maintaining normal blood pressure. A major modification that occurs during aging and is accelerated during menopause is termed vascular endothelial dysfunction which is characterized by impaired endothelium-dependent dilation. This can lead to increased blood pressure, atherosclerosis, and increased risk of CVD and death. Nitric oxide (NO) is a chemical produced by the endothelium and is essential for normal endothelial function and cardiovascular health. Vascular endothelial dysfunction is primarily caused by reduced NO bioavailability secondary to excessive oxidative stress. Approximately 3/4 of postmenopausal women have elevated blood pressure or hypertension which further worsens endothelial function and increases CVD risk through increased oxidative stress and inflammation. Blueberries are rich in phytochemicals including anthocyanins, phenolic acids, and pterostilbene. These phytochemicals and their metabolites are known to attenuate oxidative stress and inflammation. The overall goal of the current study is to assess the efficacy of blueberries to improve vascular endothelial dysfunction in this high-risk population and to gain insight into underlying mechanisms. 58 postmenopausal women with elevated blood pressure and stage 1-HTN and vascular endothelial dysfunction at the screening visit will be asked to consume 22 grams freeze-dried blueberry powder or placebo powder per day for 12 weeks. Vascular endothelial function will be assessed at baseline and 12 weeks. Measurements indicative of vascular nitric oxide production, oxidative stress, inflammation, cardiometabolic health, cognitive function, and blueberry phytochemical metabolism will be measured at baseline and 12 weeks. Blood pressure will be assessed at baseline and 4, 8, and 12 weeks.

NCT ID: NCT03099954 Completed - Hypertension Clinical Trials

Withings Pulse Wave Velocity and Blood Pressure Study

Start date: January 19, 2017
Phase: N/A
Study type: Observational

Measure pulse wave velocity stability in relation to time of day, day of the week, physical activity, sleep quality, stress levels and blood pressure.

NCT ID: NCT02513823 Completed - Clinical trials for Endothelial Dysfunction

Effectiveness of Vitamin D Supplementation

Start date: July 2015
Phase: N/A
Study type: Interventional

This pilot study will examine the effectiveness of vitamin D supplementation on reducing blood pressure and improving endothelial function. Premenopausal African American women will be recruited. Potential subjects will have systolic and diastolic blood pressure measured following the American Heart Association Blood Pressure Guidelines. Any individual with an average blood pressure > 140/90 mmHg will be referred to their personal physician for follow up. Participants with blood pressure readings <140/90 mmHg will be consented and then instructed to record food intake for three days to estimate usual dietary intake at baseline and at the 10th week timepoint. At the baseline clinic visit a 10 week supply of vitamin D3 supplements (2,000 IU/day; Nature Made ®) will be given to participants and log sheets provided to record supplement intake. For the baseline and the 10 week visits, participants will fast overnight and refrain from consuming any caffeinated products, vitamins, or medications that may affect vascular tone, and will refrain from smoking. Three successive systolic and diastolic blood pressure measurements and the average of the last two measurements will be calculated. Anthropometric and body fat distribution assessments will be performed. Height and weight will be measured. Percent body fat will be determined by bioelectric impedance (Tanita BF-350) by C Moore. Body mass index (BMI) will be calculated as weight in kilograms (kg) divided by height squared (m2). Pulse amplitude tonometry (PAT) will be measured with the EndoPAT 2000 (Itamar Medical Ltd) which records digital pulse wave amplitude (PWA) using fingertip plethysmography. A reactive hyperemia index (RHI) measures nitric-oxide dependent changes in vascular tone. Endothelial dysfunction is classified as a RHI < 1.67 with average normal endothelial RHI values ranging between 1.7 and 2.0. Blood will be drawn for measurement of serum 25(OH)D concentrations by chemiluminescence immunoassay( Abbott Architect). Vitamin D deficiency will be defined as serum 25(OH)D levels less than 20 ng/mL (50 nmol/L) and vitamin D insufficiency as 21 to 29 ng/mL (50 to 80 nmol/L). Descriptive statistics, including means and standard deviations for continuous variables and frequencies and percentages for categorical variables, will be calculated for study variables. To answer the primary research questions, within subjects repeated measures analysis of variance (ANOVA) tests will be conducted to test if any differences in blood pressure, serum 25(OH)D concentrations, and RHI are statistically different after 10 weeks of supplementation with 2,000 IU/d of vitamin D. Furthermore, exploratory multivariate linear regression models will be constructed to determine relationships between vitamin D status and vascular function parameters (blood pressure, RHI) before and after adjustment for age and BMI.

NCT ID: NCT00869193 Completed - Clinical trials for Elevated Blood Pressure

Effect of Grape Seed Extract on Blood Pressure

Start date: March 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether an 8-week intervention with grape seed extract is effective in reducing daytime ambulatory blood pressure in male and postmenopausal female with elevated daytime blood pressure values.